Crohn disease is a chronic idiopathic inflammatory bowel disease condition characterized by skip lesions and transmural inflammation that can affect the entire gastrointestinal tract from the mouth to the anus.
C rohn disease (CD) was first described by Dr Burrill B. Crohn and colleagues in 1932. 1 Along with ulcerative colitis (UC), it falls under the spectrum of chronic idiopathic inflammatory bowel disease (IBD). 2 A recent estimate suggests that 1.3% (3 million individuals) of the US population has a diagnosis of IBD. 3 Crohn disease is a chronic disease with an annual incidence ranging from 3 to 20 cases per 100,000. 4 The median onset of disease is age 30 years and it has 2 peaks, first between age 20 and 30 years and then a smaller peak around age 50 years. Crohn disease is characterized by discontinuous skip lesions affecting any part of the gastrointestinal tract from the mouth to the anus. The inflammation is classically transmural and on pathology granulomas may be present on biopsies. 5 Presenting symptoms are variable but can include diarrhea, abdominal pain, weight loss, nausea, vomiting, and sometimes fevers or chills. 6 The natural history of the disease is one of periods of remission and flares. There are multiple different phenotypes of disease including inflammatory, stricturing, and penetrating. Patients can have 1 or more of these disease phenotypes during the course of their disease, and patients often progress from inflammatory to stricturing or penetrating. Unfortunately, there is no cure for CD and most patients require at least 1 surgical resection. 5 The goal of medical therapy is to achieve a steroid-free clinical and endoscopic remission with the hopes of preventing complications and surgery. Until recently, medication options were limited to thiopurines, methotrexate (MTX), natalizumab, and antietumor necrosis factor (anti-TNF) agents. Of late, drugs with novel mechanisms of action have been approved including a gut-selective antiintegrin (a4b7) inhibitor and a monoclonal antibody to IL-12/IL-23. For this review article, we performed a review of articles in PubMed through February 1, 2017 , by using the following Medical Subject Heading terms: crohns disease, crohn's disease, crohn disease, inflammatory bowel disease, and inflammatory bowel diseases.
EPIDEMIOLOGY
The prevalence of CD has an incidence of 3 to 20 cases per 100,000. 4 Crohn disease is more common in the industrialized world, particularly in North America and Western Europe, though the incidence is rising in Asia and South America. 7, 8 There may be a slightly higher predominance of CD in women and it is more common in individuals of Ashkenazi Jewish origin than in non-Jews. The exact pathogenesis of CD is unknown, although there are a number of genetic and environmental factors that have been shown to increase the risk of the disease and lead to the aberrant gut immune response characteristic of the disease. 7 
RISK FACTORS
Risk factors for the development of CD appear to be related to changes in the gut microbiome or disruptions to the intestinal mucosa and genetics.
Environmental Risk Factors
Crohn disease appears to be triggered by alterations in the gut microbiome or disruption in the intestinal mucosa. 8 Patients with IBD often have a dysbiosis that results in a reduction in the diversity of the gut microbiome. 9 Although the literature surrounding the specifics is evolving, the exact mechanism by which alterations in the gut microbiome predispose to CD is still not fully understood.
Gastrointestinal infections, nonsteroidal anti-inflammatory drugs, and antibiotics have all been implicated in the development of IBD. 7, 8, [10] [11] [12] However, none of these associations has been substantiated with large epidemiological studies. In one study, patients with enteric infections from salmonella or campylobacter had an increased risk of developing IBD within the first year of their illness. 10 Also, sustained use of nonsteroidal antiinflammatory drugs, especially in women, may increase the risk of IBD.
11 Antibiotic exposure early in life has also been associated with an increased risk of developing CD. 13 In women, both hormone replacement therapy and oral contraceptives may increase the risk of IBD. 12, 14, 15 The best-studied environmental risk factor, cigarette smoking, doubles the risk of developing CD. 16 This risk is increased in both current and former smokers. 17 Studies have also suggested that appendectomy may increase the risk of CD but this may be due to inaccurate classification of appendicitis which in truth was actually CD. 18 The role of diet in the development of CD also remains unclear. Some studies have suggested that diets high in sugar, omega-6 fatty acids, polyunsaturated fatty acids, total fat, oil, and meat increase the risk of CD whereas a diet high in fiber and fruit decreased the risk of CD. [19] [20] [21] However, further studies are still needed to clarify the role of diet and the risk of developing CD.
Genetic Risk Factors
Although family history does portend an increased risk, only 10% to 25% of patients with IBD have a first-degree relative with the disease. 7 In twin studies, concordance rates for CD in monozygotic twins range from 20% to 50% compared with 10% in dizygotic twins. [22] [23] [24] [25] Crohn disease is more common in patients of Ashkenazi Jewish origin than in non-Jews and is less frequently seen in African Americans or Hispanics. 7 Although genetic risk factors are still being elucidated, there are more than 200 genes that have been [26] [27] [28] A number of other genetic foci involving multiple different pathways (eg, autophagy, adaptive immunity, and epithelial function) have also been associated with CD. [29] [30] [31] LOCATION OF DISEASE, DISEASE SUBTYPE, AND SEVERITY OF DISEASE Crohn disease is characterized on the basis of disease location and phenotype.
Location of Disease
Crohn disease can affect any part of the gastrointestinal tract. 5 Fifty percent of patients have involvement of the terminal ileum and the colon, 30% have only small-bowel involvement, and in 20% of cases it is isolated to the colon. In addition, 25% of patients suffer from perianal complications including fissures and fistula. Much less frequently (<10%), patients may present with isolated perianal complaints, upper gastrointestinal disease, or extraintestinal manifestations (EIMs) of disease. 5 
Disease Phenotype
For research and treatment purposes, CD has been divided into phenotypic subtypes: inflammatory, stricturing, and fistulizing. Inflammatory CD is characterized by inflammation of the gastrointestinal tract with no evidence of stricturing or fistulizing disease. This inflammation can eventually lead to fibrosis and luminal narrowing and these patients become classified as having stricturing disease. Once fibrostenotic changes occur, there is no process that reverses this aside from surgical intervention. Ongoing transmural inflammation can also result in the development of a sinus or fistulous tract characteristic of fistulizing CD. Fistulae can develop between the bowel and any adjacent organ (including the vagina, bladder, and other areas of the bowel). If the sinus tract is not complete between the bowel and an adjacent organ, an intraabdominal abscess may develop. In addition to these subtypes, patients can develop perianal complications. Perianal disease is not considered its own phenotype but rather a complication that can develop regardless of the underlying luminal disease phenotype. 5 To standardize disease classification, the Montreal Classification is used (Table 1 ). This system factors in the age at diagnosis, location of the CD, and behavior (phenotype) of the disease.
Signs and Symptoms
Presenting symptoms are quite variable but may correlate with disease phenotype and location to some extent. Some patients may have symptoms for years before the diagnosis of CD. 32 Patients with inflammatory disease often present with abdominal pain and diarrhea, though they may develop more systemic symptoms including weight loss, low-grade fevers, and fatigue. Often patients with stricturing disease develop bowel obstructions (most commonly, small bowel). Bowel obstructions are characterized by lack of flatus and bowel movements, hyperactive bowel sounds, and nausea and vomiting. Patients with penetrating CD can develop fistula or abscesses. When an abscess is present, in addition to abdominal pain, patients can have systemic symptoms such as fever and chills. Patients may also present with signs of acute peritonitis. Penetrating disease may also result in symptoms related to the fistula location: diarrhea in cases of enteroenteric fistula, urinary tract infection from enterovesicular or enterouretheral fistula, or passage of stool from the vagina in cases of enterovaginal fistula, or drainage from the skin in enterocutaneous fistula. In cases of severe CD colitis, bloody stool may be present but classically 34 Multiple tests have been evaluated to assess for inflammation in the gastrointestinal tract including fecal calprotectin or fecal lactoferrin. 35 However, none of these tests is unique to IBD and can be elevated with any intestinal infection or inflammatory condition. 34 
EIMs of Disease
Crohn disease is associated with EIMs that can affect the skin, joints, eyes, liver, blood vessels, and kidneys. 36 Arthritis is the most common EIM affecting up to 25% of patients with CD. It can involve both the peripheral and axial skeleton. The peripheral arthropathies are further categorized as type I and type II arthritis. 36 Type I is an acute, pauciarticular arthritis involving fewer than 6 joints that usually flares with luminal disease activity. This type of arthritis is self-limited and improves with treating the underlying CD. Type II arthritis involves more than 6 joints and can be chronic in nature. Although symptoms may start with luminal disease flares, it is usually independent of disease activity and can persist after the luminal CD is treated. These symptoms are often migratory. There is no synovial destruction associated with IBD-associated arthritis. 36 Axial arthropathies include ankylosing spondylitis and sacroiliitis. 36 These conditions limit spinal flexion and can be very debilitating. Presenting symptoms are morning stiffness and pain, which are relieved with exercise.
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The 2 most common skin lesions associated with CD are erythema nodosum and pyorderma gangrenosum. In most cases, erythema nodosum mirrors the luminal disease activity, whereas pyorderma gangrenosum is independent of luminal disease activity. 37, 40, 41 Primary sclerosing cholangitis is also associated with IBD and more commonly seen in UC but may also occur in CD. 42 It does not parallel luminal disease. Primary sclerosing cholangitis can be a progressive disease with complications including cirrhosis, portal hypertension, cholangiocarninoma, and colon cancer. 43 Multiple other conditions have been associated with CD including uveitis, scleritis, osteoporosis, psoriasis, depression, nephrolithiasis, B 12 deficiency, deep vein thrombosis, chronic bronchitis, bronchiectasis, and impaired growth in children. 36, 37, 40, 41 DIFFERENTIAL DIAGNOSIS Many conditions can mimic CD. All patients with diarrhea should be assessed for infection, IBD, and in certain cases celiac disease as well. Other conditions that may present similar to CD include appendicitis, Behcet disease, and UC. It is important to rule out infection and other causes of gastrointestinal symptoms even when patients with known CD are having "flares."
DIAGNOSIS
The diagnosis of CD is a clinical one and can be quite difficult given that the presenting symptoms can be insidious and nonspecific. 5 Red flag symptoms that require further evaluation include weight loss, bloody diarrhea, iron deficiency, and night-time awakenings. Similarly, significant family history of IBD, unexplained elevations in the c-reactive protein level, sedimentation rates, or other acutephase reactants (eg, ferritin and platelets), or low B 12 should prompt further investigation for possible CD.
The diagnosis of CD is made on the basis of symptoms and endoscopic and radiologic findings. 5, 33 Pathology can be confirmatory. In cases of colonic or ileal CD, endoscopic findings are classically characterized by skip lesions, with varying degrees of inflammation (including erythema, friability, erosions, and ulcers) next to areas of normal-appearing mucosa. During endoscopy, luminal strictures, and less commonly fistulae, may be seen. On pathology, the classic finding of CD is a noncaseating granuloma (Figure 1 ). However, these are rare, occurring in less than 25% of cases and are not unique or pathognomonic to CD. 44, 45 More common pathologic findings include varying degrees of infiltrates from lymphocytes, plasma cells, granulocytes, basal lymphoplasmacytosis, distortion of the crypt architecture with shortening and disarray of the crypts, crypt atrophy, crypt abscesses, and crypt branching. The pathologic finding of chronicity is also supported by the presence of paneth cell metaplasia. 5 In certain cases, such as isolated jejunal disease, the affected area may not be amenable to easy endoscopic evaluation. In these cases, balloon enteroscopy or capsule endoscopy can be performed to assess the small-bowel mucosa. 46 Although capsule endoscopy is a very sensitive test for finding abnormal mucosa, it has low specificity for diagnosing CD and has the risk of becoming retained or impacted in cases of stricturing CD. 47, 48 The risk of capsule retention in cases of suspected CD is quite low at 1.6%, but this risk increases to 13% in cases of known CD. 48 To mitigate this risk, smallbowel imaging and a patency capsule should be placed before performing a capsule endoscopy. The patency capsule is specially designed to disintegrate within 48 to 72 hours. Imaging is obtained 24 hours after placement to identify the radiopaque markers on the patency capsule to determine whether it passed through the small bowel. If this passed through, then the regular capsule endoscopy can likely be performed without significant risk of being retained. 49 Imaging can also be used to diagnose CD. Both computed tomography enterography (CTE) and magnetic resonance enterography (MRE) allow for visualization of the bowel wall, mucosa, and extraluminal complications (Figure 2) . The CTE and MRE have supplanted small-bowel barium studies as the criterion standard for the diagnosis and assessment of CD. 50 Compared with CTE, MRE is more expensive but importantly, it avoids radiation exposure and does not use iodinated contrast.
Although a number of studies have evaluated the use of serologic markers in diagnosing CD, 51, 52 no marker or panel of markers is sensitive or specific enough to establish or rule out the diagnosis of CD.
TREATMENT
The treatment of CD depends on disease severity, location of disease, and subtype of disease (ie, inflammatory, stricturing, or penetrating). We now also attempt to determine who is at risk for aggressive CD and who may require earlier and more aggressive therapies. Risk factors for aggressive disease activity include age of diagnosis less than 30 years, extensive anatomic involvement, perianal disease, deep ulcers, prior surgery, and stricturing and/or penetrating disease. 53 One of the biggest challenges associated with CD is that after 20 years of disease activity 80% of patients will require a surgery and approximately 30% will require surgery within 5 years of diagnosis. 5, 54 Although the goal of medical therapy is to maintain remission without the need for surgery, once stricturing and/or fistulizing complications occur, surgery may be required. Unfortunately, because surgery is not curative for CD, many patients will require multiple surgeries over their lifetime. 54 There are a number of different drugs used to treat CD. Mesalamine has been evaluated in a number of studies but has not been shown to effectively induce or maintain remission in CD. The perceived benefit of mesalamine is likely related to its safety profile. 5 Antibiotics
are also used in CD, but the evidence supporting their use is also limited. 55 The main role of antibiotics is to treat the suppurative or perianal complications of CD. 56 The immunosuppressants azathioprine (AZA)/mecaptopurine (MP) and MTX have been used for many years to treat CD but because of slow onset of action they are typically used to maintain remission. However, more recent studies question the overall efficacy of AZA/MP as monotherapy and their use in early CD. [57] [58] [59] More recently, these drugs are used in combination with anti-TNF drugs to decrease their immunogenicity and increase anti-TNF drug concentrations. The mainstay of therapy for CD has been anti-TNF agents. More recently approved drugs are monoclonal antibodies directed against certain integrins (a4 or a4b7) or interleukins (IL-12/IL-23). The first antiintegrin approved for CD was natalizumab, but this is associated with progressive multifocal leukoencephalopathy (PML), a fatal brain infection. 60, 61 Vedolizumab is a gutselective antiintegrin that has not been associated with PML and is used mostly to maintain remission in moderate to severe CD with only modest effectiveness at induction of remission. 62 In contrast, the most recently approved agent, ustekinumab, an IL-12/IL-23 inhibitor, has been shown to be as effective as anti-TNF therapy at inducing and maintaining remission in moderate to severe CD. 63 Ultimately, the goal of medical therapy is to induce and maintain a steroid-free clinical remission, prevent complications and surgery, and improve the patient's quality of life. 64 For typical medication, complications, and monitoring recommendations, see Table 2 .
5-Aminosalycilates
In general, studies suggest that mesalamine is ineffective in the treatment of CD and should not be used. 65 Although there are some data that sulfasalazine may be modestly effective for induction of remission in colonic CD, it has not been shown to maintain remission. 66 Despite this finding, mesalamine is still one of the most commonly prescribed drugs for CD. 67 Although studies are lacking, some physicians do use mesalamine in patients with mild colonic CD that appears similar to UC. The data supporting this technique are limited but the safety profile of mesalamine makes it quite intriguing to use. 5 If the drug is going to be efficacious, symptoms should start to improve in 2 to 4 weeks. 68 If induction of remission is achieved, mesalamine should be continued to maintain remission. However, if ineffective after a few weeks, other therapies should be initiated. Patients should not be kept on an ineffective medication just because it is perceived to be safe. Side effects are rare. In less than 5% of cases, patients may have a paradoxical reaction causing increased diarrhea, in which case the drug should be stopped and no other mesalamine agent should be used, because this is a class effect. In less than 1% of patients treated with mesalamine, interstitial nephritis may occur and episodic checking of renal function is recommended. 69 Antibiotics Similar to mesalamine, antibiotics have not been shown to be effective for induction and maintenance of remission for active CD. 70 The best data for antibiotics are in the short-term treatment of perianal fistula and in combination with anti-TNF for perianal CD. 71 Aside from these indications, antibiotics should really be used to treat the suppurative complications of CD. 55, 71 The most commonly used agents are ciprofloxacin and metronidazole. 55, 72 The main limitations to using these agents long-term are antibiotic resistance and side effect profile.
Corticosteroids
Steroids are used to induce remission but are not an effective maintenance agent. 73, 74 Multiple steroid formulations are available including intravenous steroids, prednisone, and the less systemically absorbed budesonide (enteric coated). 75, 76 Although budesonide is ideal to use given its improved side effect profile, its efficacy is limited to mild-moderate ileal and right-sided colonic CD. 77 Steroids have a quick onset of action and are generally effective at inducing remission in CD but have no role in the maintenance of disease remission. In addition, steroids are also ineffective in treating perianal CD. 55, 78 Patients treated with systemic steroids should be transitioned to a medication proven to maintain remission in CD, and prolonged courses of steroids should be avoided. Unfortunately, steroids have numerous side effects including adrenal insufficiency, obesity, cataracts, glaucoma, hypertension, diabetes, and so forth (Table 2) . 5, 55, 78, 79 In addition, several studies have demonstrated that systemic corticosteroids increase the risk of serious infection and mortality in patients with moderate to severe CD.
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Immunosuppressants Thiopurines. Thiopurines (AZA and MP) are more commonly used to maintain remission as opposed to induction of remission. 53, 58, 82, 83 A Cochrane review of the literature found that both AZA and MP were no better than placebo for induction of remission or clinical improvement in ongoing active CD. 83, 84 In addition, more recent data question the overall efficacy of earlier use of thiopurines in CD, which may not be effective in altering the natural history of the disease. 57, 59 Although recent studies cast doubt on the overall efficacy of thiopurines in CD, the most recent American Gastroenterological Association (AGA) guidelines for drug therapy in CD include them as an option for maintaining remission in moderate CD. 53, 57, 59 However, in a head-to-head trial, AZA was shown to be less effective than infliximab monotherapy or the combination of AZA and infliximab at maintaining a steroid-free remission. 85 Because thiopurines do not work quickly and take approximately 6 to 12 weeks to achieve response, steroids are typically used to induce remission and steroids are continued during this time to ensure that the patient will not flare while transitioning to a thiopurine. Importantly, before thiopurines are started, thiopurine methyltransferase (TPMT) enzymatic activity should be assessed to evaluate how the patient's liver metabolizes the drug. [86] [87] [88] If a patient has intermediate TPMT enzymatic activity, then the initial dose of AZA or MP should be lower by 25% to 50%. For the 0.3% of the population that lacks all TPMT activity, AZA and MP should be avoided. 89 In addition, in patients younger than 25 years, Epstein-Barr virus should be checked and if negative then the drug should probably be avoided given an increased risk of hemophagocytic lymphohistiocytosis and primary thyroid lymphoma. 90, 91 The use of thiopurines is limited by their side effect profile. Around 15% to 20% of patients discontinue the drug because of side effects. 91, 92 See Table 2 for full details. Both cytopenias and transaminitis can be seen at any point in time and routine laboratory testing to screen for this is recommended. These side effects are typically related to the drug metabolism, and drug metabolites can be clinically checked in these situations. 93 Other side effects that may occur at the time of initiation include nonspecific nausea and vomiting and an allergy or acute pancreatitis. Thiopurines also increase the risk of nonmelanoma skin cancers, cervical dysplasia, lymphoma, and heptosplenic T-cell lymphoma. 91, 93, 94 Methotrexate. Methotrexate can be used both for induction of remission and for maintenance of remission. 83, 95, 96 For induction of remission, only the subcutaneous injection was found to be effective. 96 For maintenance of remission, MTX appears to be slightly more effective than AZA or MP. 83 Onset of action is within 8 to 16 weeks. 97 Side effects are not uncommon with the use of MTX. In one study, MTX was discontinued in 17% of patients as a result of adverse effects. 95 Methotrexate is associated with a number of nonspecific symptoms including nausea, vomiting, headaches, and fatigue. Similar to thiopurines, it can be hepatotoxic and in rare cases cause myelosuppression. Routine laboratory testing is recommended to monitor for these potential adverse events. Methotrexate also has an antifolate effect that can result in anemia and stomatitis. When taking MTX, concomitant administration of daily folic acid is recommended. 97 Similar to thiopurines, MTX appears to be associated with an increased risk of both nonmelanoma skin cancer and lymphoma. 98, 99 In addition, MTX is contraindicated during pregnancy because it is both an abortifacient and teratogenic. 5 Anti-TNF Agents. To date, anti-TNF therapy appears to be our most effective therapy for moderate to severe CD and can be used alone or in combination with an immunomodulator to induce and maintain remission. 5, 33, 85, 100 Currently, 3 anti-TNF agents are Food and Drug Administration (FDA) approved for moderate to severe CD: infliximab, adalimumab, and certolizumab pegol. [101] [102] [103] Infliximab is a chimeric anti-TNF antibody that is administered intravenously. Adalimumab is a fully humanized monoclonal antibody that is administered subcutaneously by self-injection. 104 Certolizumab pegol is an FaB antibody fragment of a humanized anti-TNF molecule that is also self-administered subcutaneously. Before an anti-TNF agent can be started, patients need to have latent tuberculosis and hepatitis B infection ruled out. 105 If either infection is identified, then the patient should be referred to a specialist before starting anti-TNF therapy.
There have not been any head-to-head trials of anti-TNF agents, but there are some data suggesting that infliximab is associated with fewer hospitalizations, surgeries, and steroid use compared with other anti-TNF agents in CD. 106 In general, patient and physician preference should decide which anti-TNF agent is chosen. However, insurance companies often have a preferred anti-TNF agent that ultimately dictates which agent is used. Nevertheless, for fistulizing CD, infliximab is the only agent with a phase 3 study demonstrating efficacy and a specific FDA indication. This is why many physicians consider infliximab the preferred agent for fistulizing CD, particularly for perianal fistulizing disease. 102 Anti-TNF agents work quickly and some response may be seen within the first week of treatment (eg, infliximab) but the therapeutic effect may take up to 6 weeks.
If the patient's disease flares while taking an anti-TNF agent, drug concentrations and antidrug antibodies (ADAs) can be checked to determine whether patients require more drug (low drug concentrations and no/low ADAs), a switch to another anti-TNF agent (high ADAs), or need to be switched to a different drug class (adequate anti-TNF drug concentrations). 107 This treatment paradigm has been shown to better direct care and is more cost-effective than empiric dose escalation. 107 Furthermore, there is some evolving evidence that proactive dose optimization and treating to a therapeutic window may improve outcomes and be cost-effective. 107, 108 Current AGA guidelines advocate for the use of combining an anti-TNF agent with a thiopurine or MTX. 53 This combination has been shown to increase the anti-TNF drug concentrations while also minimizing the risk of developing ADA. 60, 61 However, this combination is associated with an increased risk of side effects including opportunistic infection. 5, 33 To assist in determining in whom combination therapy is appropriate, the BRIDGe group has developed an algorithm that incorporates the risks and benefits of combination therapy (http://www.bridgeibd. com/mono-versus-combo-therapy). 109 The 3 anti-TNF agents have similar safety profiles. 104 The most common side effects are injection-site/infusion reactions and an increased risk of infection. 110, 111 Although less common than with thiopurines and MTX, there are rare cases of cytopenias and liver toxicity and routine laboratory testing is recommended. Although there is a slightly increased risk of melanoma with anti-TNF use, the risk of other malignancies is unclear. 112 When anti-TNF and thiopurines or MTX are used in combination, side effects related to both anti-TNF and thiopurine or MTX must be reviewed with the patient as well as the increased risk of opportunistic infection. 91, 100, 113 In addition, there is a rare risk of hepatosplenic T-cell lymphoma with the combination of thiopurines and anti-TNF. 114 Although extremely rare, this risk is greatest in male patients younger than 35 years and after 2 years of combination therapy. 33 Selective Adhesion Molecule Inhibitors. Vedolizumab is the first gut-selective adhesion molecule inhibitor for use in moderate to severe CD. 62 It is a humanized monoclonal IgG antibody that targets the adhesion molecule a4b7-heterodimer, inhibiting leukocyte migration. 115 A similar agent, natalizumab, was the first adhesion molecule approved for moderate to severe CD. However, natalizumab blocks the a4 integrin, which is not gut specific, and carries a risk of PML, a viral brain infection that results in severe disability and death. In contrast, no cases of PML have been reported to date with vedolizumab. 62, 115 Vedolizumab can be used for induction of remission, but the onset of action is quite slow and its efficacy is quite limited. 62 However, patients who have an initial response to therapy will then maintain this remission at 1 year. 62 An initial response is typically seen within 12 weeks of starting the drug. 62 In addition, because vedolizumab is gut selective, there does not appear to be an increased risk of serious adverse events or infections other than nasopharyngitis. 62 Interleukin Inhibitor. Ustekinumab is the latest drug approved for moderate to severe CD (October 2016) though it has been FDA approved for psoriasis since 2009. Ustekinumab is a fully humanized monoclonal antibody to the p-40 subunit of IL-12 and IL-23. The drug is administered as a one-time weight-based infusion followed by subcutaneous injections every 8 weeks. Similar to anti-TNF agents, before starting this drug, patients should be tested for latent tuberculosis and hepatitis B. Its overall efficacy appears to be on par with anti-TNF therapy for both induction of remission and maintenance of remission. 63, 102, 104, 116 Ustekinumab also seems to have a similar onset of action and response is usually seen within 6 weeks. Based on the trials to date in CD and the postmarketing data for psoriasis, ustekinumab does not appear to increase the risk of serious infection. 117 However, the studies in CD are relatively short-term and the dose used for psoriasis is less than the dose approved for CD.
Surgery
Most patients with CD will undergo surgery during the course of their disease. 5, 33, 118 Surgery is indicated in a number of situations including stricturing CD with obstructive symptoms, fistulizing or perianal CD with infectious complications or issues related to the drainage of the fistula, failure of medical therapy, steroid dependence, dysplasia, or cancer. 119 The exact surgical procedure depends on the underlying indication for the surgery.
Stricturing CD. No medical therapy reverses the fibrostenotic changes that cause strictures. In patients who have ongoing obstructive symptoms, surgical resection of the stricture may be indicated. 78 Because surgery is not curative, the goal is to remove the smallest amount of bowel possible and perform a primary anastomosis. When there are numerous strictures, removal of all of them may not be feasible. In these cases, the most prominent stricture may be resected while the others may either be dilated intraoperatively or a stricturoplasty may be performed. 78, 119 Fistulizing CD. For enteroenteric fisulae, as long as the fistula is not causing a direct complication, it is rarely intervened upon. However, in cases of enterovesicular fistulae, enterovaginal fisulae, or enterocutaneous fistulae, bowel resection and fistulotomy are often required. 120 Also, if a sinus tract is present and an abscess forms, then radiologic or surgical drainage of the abscess may be required as well. 120 Perianal CD. Perianal CD can present as an anal fissure, perianal fistula, or perirectal abscess. Both perianal fistula and abscess often require surgical intervention with drainage and placement of a seton. Anal fissures are typically treated medically with therapy for CD but if they do not respond then a fissurotomy can be considered or in some cases botulinum toxin injections may also be used.
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Postoperative Medical Therapy. Unfortunately, about 50% of patients will develop a clinical recurrence within 5 years of their surgery and as many as 40% will require a second surgery within 10 years. 5, 33 Ideally, drug therapy is used to prevent this clinical recurrence. 122 However, the overall efficacy of using pharmacologic therapy to prevent clinical recurrence of CD following surgery is unclear. 122, 123 The most robust data are with the use of anti-TNF therapy. 124 Classically, patients will undergo a colonoscopy 6 to 12 months after surgery to assess for endoscopic recurrence and to perform a Rutgeerts scoring system to predict the likelihood of clinical recurrence in the next 1 to 5 years (Table 3) . 125 However, in patients who are at high risk of early clinical recurrence (Table 4) , some physicians opt to place patients on immediate postoperative medication. 126 Regardless, ongoing colonoscopic assessment for recurrence is recommended.
OTHER DISEASE COMPLICATIONS
Patients with CD colitis involving at least onethird of the colon are at an increased risk of colon cancer and require ongoing surveillance. 33 If colonic disease is present, then current guidelines from the AGA recommend initiating screening 8 years after diagnosis. 127 Surveillance colonoscopy is necessary only in those with more than one-third of their colon involved. This is performed every 1 to 3 years with segmental biopsies throughout the colon. 127 Patients with ileal disease are also at a significantly increased risk of small-bowel carcinoma, but the overall risk is still low, and no screening is recommended. 128 Quality Measures in CD and the Role of the Primary Care Physician Crohn disease can be associated with significant morbidity and many patients require pharmacologic therapy to suppress the immune system to maintain disease-free remission. To minimize the risk of iatrogenic complications, primary care physicians and gastroenterologists need to comanage these patients to optimize their management. In 2011, the AGA developed a list of quality measures to improve the care of patients with IBD. 105 Eight of the 10 measures focus on the management of outpatients with IBD. Multiple quality measures can be comanaged by gastroenterology and primary care: screening for tobacco abuse and counseling patients to quit if they are smoking, yearly influenza vaccination, pneumococcal vaccination, and assessment for bone loss with a bone density scan in those patients exposed to the equivalent of prednisone 10 mg/d or more for 60 days or more. 105 In a recent study, our group noted that compliance with these quality measures was poor across different practice types including academic practice, community practice, and private practice. 129 The importance of preventing iatrogenic complications is of utmost importance when treating patients with immunosuppressants. At our institution we also recommend that patients be optimized with all relevant vaccinations including tetanus, diphtheria, acellular pertussis, human papilloma virus, hepatitis A and B vaccination, varicella, and zoster vaccination after age 50 years. [130] [131] [132] [133] However, live vaccines, varicella and zoster, should not be administered to those on immunosuppressive or biologic therapies. Likewise, in our practice to further mitigate the risk of drug-related complications, 94, 98, 134 Finally, in females on a thiopurine, an yearly pap smear is recommended given the increased risk of cervical dysplasia. 135 
CONCLUSION
Crohn disease is a chronic IBD that can affect any portion of the gastrointestinal tract. It is typically medically managed, but a significant percentage of patients will require surgery. The goals of care are to induce and maintain a steroid-free remission, decrease the risk of complications and surgery, and also improve the overall quality of life. To this end, patients with CD are best comanaged with primary care physicians to help optimize their primary prevention and reduce their risk of complications. Being aware of the subtypes and natural history of CD as well as the potential complications of the disease and the medication used to treat the disease is critical to optimizing the health care of patients with CD.
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